Pulmonary hypertension related to drugs and toxins

Current Opinion in Cardiology

Volumn 14, Issue 5, 1999, Pages 437-441

  Abenhaim, Lucien ^a,c   Humbert, Marc ^b  

^a MCGILL UNIVERSITY   (Canada)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOREX; ANOREXIGENIC AGENT; CARMUSTINE; CHLORPHENTERMINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FENFLURAMINE; INDOMETACIN; MITOMYCIN C; MONOCROTALINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENFORMIN; PHENMETRAZINE; PHENTERMINE; RAPESEED OIL; TOXIN; TRYPTOPHAN;

HUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SUBSTANCE ABUSE; SYMPOSIUM;

ANGIOSPERMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APPETITE DEPRESSANTS; BRASSICA; CONTRACEPTIVES, ORAL; DESIGNER DRUGS; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; PLANT OILS; TOXINS, BIOLOGICAL; TRYPTOPHAN; WORLD HEALTH;

EID: 0032844284     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199909000-00013     Document Type: Review

References (53)

1. Rich S, Rubin LJ, Abenhaim L, Barst RJ, Brundage BH, Fishman AP, et al.: Executive summary from the World Symposium on Primary Pulmonary Hypertension (Evian, France, September 6-10, 1998). The World Health Organization publication via the Internet (http://www.who.int/ncd/cvd/ pph.html).
2. Gurtner HP: Aminorex and pulmonary hypertension. Cor Vasa 1985, 27:160-171.
3. Follath F, Burrart F, Schweizer W: Drug-induced pulmonary hypertension? Br Med J 1971, 1:265-266.
4. Kay JM, Smith P, Heath D: Aminorex and the pulmonary circulation. Thorax 1971, 26:262-269.
5. Loogen F, Worth H, Schwan G, Goeckenjan G, Losse B, Horstkotte D: Long-term follow-up of pulmonary hypertension in patients with and without anorectic drug intake. Cor Vasa 1985, 27:111-124.
6. Gurtner HP: Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? Bull Physiopathol Respir (Nancy) 1979, 15:897-923.
7. Douglas JG, Munro JF, Kitchin AH, Muir AL, Proudfoot AT: Pulmonary hypertension and fenfluramine. Br Med J 1981, 283:881-883.
8. Pouwels HM, Smeets JL, Cheriex EC, Wouters EF: Pulmonary hypertension and fenfluramine. Eur Respir J 1990, 3:606-607.
9. McMurray J, Bloomfield P, Miller HC: Irreversible pulmonary hypertension after treatment with fenfluramine [letter]. Br Med J 1986, 293:51-52.
10. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G: Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993, 70: 537-541.
11. The International Primary Pulmonary Hypertension Study Group: The international primary pulmonary hypertension study (IPPHS). Chest 1994, 105(suppl):37-41.
12. Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC: Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997, 337(9):602-606.
13. McTavish D, Heel RC: Dexfenfluramine, a review of its pharmacological properties and therapeutic potential in obesity. Drugs 1992, 43:713-733.
14. Martin F, Artigas F: Simultaneous effect of p-chloroamphetamine, d-fenfluramine, and reserpine on free blood and stored 5-HT in brain and blood. J Neurochem 1992, 59:1138-1144.
15. Hervé P, Launay J-M, Scrobohaci M-L, Brenot F, Simonneau G, Petitpretz P, et al.: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995, 99:249-254.
16. Voelkel NF: Appetite suppression and pulmonary hypertension. Thorax 1997, 52(suppl):63-67.
17. Fuller RW: Serotonin uptake inhibitors: use in clinical therapy and in laboratory research. Prog Drug Res 1995, 45:167-204.
18. Curzon G, Gibson EL, Oluyomi AO: Appetite suppression by commonly used drugs depends more on 5-HT receptors but not on 5-HT availability. Trend Pharmacol Sci 1997, 18:21-25.
19. Weir EK, Reeve HL, Huang JMC, Michelakis E, Nelson DP, Hampl V, Archer SL: Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 1997, 94:2216-2220.
20. Bonev AD, Nelson MT: Vasoconstrictors inhibit ATP-sensitive K+ channels in arterial smooth muscle through protein kinase C. J Gen Physiol 1996, 108:315-323.
21. Naeje R, Wauthy P, Maggiorini M, Leeman M, Delcroix M: Effects of dexfenfluramine on hypoxic vasoconstriction and embolic pulmonary hypertension in dogs. Am J Respir Crit Care Med 1995, 151:692-697.
22. Backman R, et al.: Primäre pulmonale hypertonie. In Verhandlungen der deutschen gesellschaft für kreislaufforschung. Darmstadt, Germany: Steinkopff Verlag; 1972:134-141.
23. Niebyl JR: Drug therapy during pregnancy. Curr Opin Obstet Gynecol 1992, 4:43-47.
24. Besinger RE, Niebyl JR, Keyes WG, Johnson TR: Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol 1991, 164:981-986; discussion, 986-988.
25. Dalens B, Dechelotte P, Gaulme J, Raynaud EJ: Maternal treatment with indomethacin and severe neonatal pulmonary hypertension. Arch Fr Pediatr 1981, 38:261-265.
26. Niebyl JR, Blake DA, White RD, Kumor KM, Dubin NH, Robinson JC, Egner PG: The inhibition of premature labor with indomethacin. Am J Obstet Gynecol 1980, 136:1014-1091.
27. Zuckerman H, Shalev E, Gilad G: Further study of the inhibition of premature labor by indomethacin. J Perinat Med 1984, 12:25-29.
28. Morales WJ, Smith SG, Angel JL, O'Brien WF, Knuppel RA: Efficacy and safety of indomethacin versus ritodrine in the management of preterm labor: a randomized study. Obstet Gynecol 1989, 74:567-572.
29. Wilkinson AR, Aynsley-Green A, Mitchell MD: Persistent pulmonary hypertension and abnormal prostaglandin E levels in preterm infants after maternal treatment with naproxen. Arch Dis Child 1979, 54:942-945.
30. Joselson R, Warnock M: Pulmonary veno-occlusive disease after chemotherapy. Hum Pathol 1983, 14:88-91.
31. Waldhom RE, Tsou E, Smith FP, Kerwin DM: Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. Med Pediatr Oncol 1984, 12:394-396.
32. Hackman RC, Madtes OK, Petersen FB, Clark JG: Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989, 47:989-992.
33. Fahlen M, Bergman H, Helder G, Ryden L, Wallentin I, Zettergren L: Phenformin and pulmonary hypertension. Br Heart J 1973, 35:824-828.
34. Kleiger RE, Boxer M, Ingham RE, Harrison DC: Pulmonary hypertension in patients using oral contraceptives: a report of six cases. Chest 1976, 69:143-147.
35. Masi AT: Pulmonary hypertension and oral contraceptive usage. Chest 1976, 69:451-453.
36. Devathasan G, Low D, Teoh PC, Wan SH, Wong PK: Complications of chronic glue (toluene) abuse in adolescents. Aust NZ J Med 1984, 14:39-43.
37. Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL: Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 1993, 104:614-616.
38. Russell LA, et al.: Pulmonary hypertension in female crack users. Am Rev Respir Dis 1992, 145:A717.
39. Collins E, Hardwick H, Jeffery H: Perinatal cocaine intoxication. Med J Aust 1989, 150:331-332.
40. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. for the International Primary Pulmonary Hypertension Study Group: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996, 335:609-616.
41. Fishman AP: Dietary pulmonary hypertension. Circ Res 1974, 35:657-660.
42. Olivari MT: Southwestern internal medicine conference: Primary pulmonary hypertension. Am J Med Sci 1991, 302:185-198.
43. Philen RM, Posada M: Toxic oil syndrome and eosinophilia-myalgia syndrome. May 8-10, 1991, World Health Organization Meeting Report. Semin Arthritis Rheum 1993, 23:104-124.
44. Diaz de Rojas F, Castro Garcia M, Abaitus Bordai, Alonso Gordo JM, Posada de la Paz M, Kilbourne EM, Tabuenca Oliver JM: The association of oil ingestion with toxic-oil syndrome in two convents. Am J Epidemiol 1987, 125:907-911.
45. Rigau-Perez JG, Perez-Alvarez L, Duenas-Castro S, Choi K, Thacker SB, Germain JL, et al.: Epidemiologic investigation of an oil-associated pneumonic paralytic eosinophilic syndrome in Spain. Am J Epidemiol 1984, 119:250-260.
46. Castro Garcia M, Posada de la Paz F, Diaz de Rojas F, Abaitua Borda I, Alonso Gordo JM, Tabuenca Oliver JM: Pulmonary hypertension after toxic rapeseed oil ingestion [letter]. J Am Coll Cardiol 1984, 4:443.
47. Alonso-Ruiz A, Calabozo M, Perez-Ruiz F, Mancebo L: Toxic oil syndrome: a long-term follow-up of a cohort of 332 patients. Medicine 1993, 72:285-295.
48. Gomez-Sanchez MA, Mestre de Juan MJ, Gomez-Pajuelo C, Lopez JI, Diaz de Atauri MJ, Martinez-Tello FJ: Pulmonary hypertension due to toxic oil syndrome: a clinicopathologic study. Chest 1989, 95:325-331.
49. Campagna AC, Blanc PD, Criswell LA, Clarke D, Sack KE, Gold WM, Golden JA: Pulmonary manifestations of the eosinophilia-myalgia syndrome associated with tryptophan ingestion. Chest 1992, 101:1274-1281.
50. Philen RM, Posada M: Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization Meeting Report. Semin Arthritis Rheum 1993, 23:104-124.
51. Tazelaar HD, Myerd JL, Drage CW, King TE Jr, Aguayo S, Colby TV: Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome: clinical and pathologic features. Chest 1990, 97:1032-1036.
52. Criswell LA, Sack KE: Tryptophan-induced eosinophilia-myalgia syndrome. West J Med 1990, 153:269-274.
53. Sack KE, Criswell LA: Eosinophilia-myalgia syndrome: the aftermath. South Med J 1992, 85:878-882.